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Objectives: Repetitive transcranial magnetic stimulation (rTMS) seems to be effective
as an antidepressant, however, some confusion remains about the best parameters to
apply and the efﬁcacy of its association with pharmacological antidepressant treatments.
Method: In a single blind randomized study 14 patients with unipolar resistant depression
to one antidepressant treatment were enrolled to receive, in combination with venlafaxine
(150mg), either 20 sessions of 10Hz rTMS (2000 pulses per session) applied over the
left dorsolateral prefrontal cortex (DLPFC) or 20 sessions of 1Hz rTMS (120 stimulations
per sessions) applied over the right DLPFC. Results: A similar antidepressant effect was
observed in both groups with a comparable antidepressant delay of action (2weeks) and a
comparable number of responders (MADRS< 15) after 4weeks of daily rTMS sessions (66
vs 50%). Conclusion: Low- and high- frequency rTMS seems to be effective as an add-on
treatment to venlafaxine as monotherapy in pharmacological refractory major depression
(stage 1). Due to its short duration (one session of 1Hz rTMS lasts 4min vs 16 for 10Hz
rTMS) and its safety, low frequency rTMSmay be a useful alternative treatment for patients
with refractory depression.
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INTRODUCTION
Depression constitutes a major public health concern with a con-
siderably high level of morbidity and mortality. Although anti-
depressant (AD) treatments have demonstrated their efﬁciency, a
substantial number of depressed patients (50–60%) respond only
partially or not at all to at least one trial of an antidepressant med-
ication (Steffens et al., 1997) and close to 20% of these patients are
refractory to any antidepressant medication (Fava, 2003). More-
over, the clinical utility of antidepressant drugs is impaired by the
delay in onset of their therapeutic action.
Most of recent studies as well as meta-analysis support an anti-
depressant effect of high frequency (HF) repetitive transcranial
magnetic stimulation (rTMS) applied to the left dorsolateral pre-
frontal cortex (LDLPFC; George et al., 2010; for review: Brunelin
et al., 2007).However there remains some confusion about the best
beneﬁcial stimulation site to target as well as the best parameters to
apply. While the impact of starting a combination between rTMS
and an AD at the same time is still poorly studied, some authors
support the hypothesis that this association could shorten the AD
treatment delay of action (Poulet et al., 2004; Rumi et al., 2005).
On the other hand, there is growing evidence thatHFLDLPFC is as
effective as low frequency (LF) rTMS applied to the right DLPFC
(RDLPFC) in the treatment of depressive episode (Höppner et al.,
2003; Isenberg et al., 2005; Stern et al., 2007; Fitzgerald et al., 2009;
Pallanti et al., 2010; Rossini et al., 2010).
We report here results from a pilot single blind double arms
controlled study investigating the antidepressant effect, in asso-
ciation with venlafaxine, of active HF (10Hz) LDLPFC rTMS
compared to active LF (1Hz) LDLPFC rTMS (150mg) in patient
with refractory depressive symptoms.
MATERIALS AND METHODS
Sixteen patientswith unipolarmajor depression according toDSM
IV were included through clinical and MINI evaluation (Mini
version 4.4). All of them gave their written informed consent
before entering the study which was approved by a regional eth-
ical committee. They were aged between 18 and 65 and have not
tried venlafaxine for the present depression episode. Patients were
recruited at the “Le vinatier” Hospital. At inclusion, all of them
present a Montgomery andAsberg (1979) Depression Rating Scale
(MADRS) score >20 despite the prescription of an AD at efﬁ-
cient dose for at least 12weeks. Patients respond to stage 1 of
treatment-resistant depression as described in Fava (2003).
Prospective patients were screened for contraindications to
rTMS, including a history of personal or family seizures, neu-
rological or neurosurgical antecedent, inner ear prosthesis, pace-
maker, and anticonvulsive medication. Electroencephalographic
and clinical examinationwasmade before the ﬁrst rTMS sequence.
Participants were randomly allocated into two groups after
2 weeks of wash out period for all medications. Venlafaxine
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(75mg/day) administration as monotherapy began 3 days before
the start of rTMS treatment. The day of the ﬁrst rTMS session,
venlafaxine was increased to 150mg on the morning. Then, one
group was treated with venlafaxine and HF-rTMS applied over the
LDLPFC and the second group was treated with venlafaxine and
LF-rTMS applied over the RDLPFC.
Stimulations were carried out using a MagPro 100 (Medtronic–
Boulogne–France) stimulator system using ﬁgure-eight 70-mm
coils. Stimulation intensity was 100% of resting motor thresh-
old. Motor threshold was identiﬁed as the minimum magnetic
ﬁeld strength required to produce left thenar muscle activation by
single transcranial magnetic pulses delivered to the motor cortex
for at least 5 of 10 trials. Coil placement was 5 cm anterior from
motor cortex (international 10–20 system). Because two patients
withdrew their consent before the start of the trial, the ﬁnal groups
were:
– High-frequency group (n = 6): Stimulation frequency was
10Hz. Eachpatient received 10,15,or 20 rTMS sessions depend-
ing on the response rate after 10 sessions, one session per day
(2 or 4weeks). Each daily session consisted in a total of 2000
pulses 40 trains of 5 s duration and 30 s intertrain intervals.
– Low frequency group (n = 8): Stimulation frequency was 1Hz.
Each patient received 10, 15, or 20 rTMS sessions depending
on the response rate after 10 sessions, one session per day (2 or
4weeks). Each daily session consisted in a total of 120 pulses of
2 trains of 60 s duration and 120 s intertrain intervals.
A psychiatrist blind to group assignment conducted all assess-
ments of patients’ symptoms. To assess antidepressant effects, we
used the 10-items MADRS. We measured MADRS scores at base-
line, after 5, 10, 15, and 20 rTMS sessions. Patients who were
responders after the ﬁrst 10 or 15 rTMS sessions (deﬁned as
MADRS score<15) did not received more rTMS sessions.
ANALYSIS
Comparisons between groups at baseline were assessed using stu-
dent t -tests except for gender (Fischer’s chi-square). Statistical
analysis was performed at a signiﬁcant threshold of 0.05 using
a repeated measures analysis of variance (ANOVA) on MADRS
scores at each assessment times. Number of responders was com-
pared between the groups using Fischer’s chi-square test. Statistics
were done using the Statistica software.
RESULTS
At baseline, the two groups did not signiﬁcantly differ for age,
sex ratio, and for MADRS scores (Table 1). No adverse event was
observed in both groups.
Number of responders did not differ in each group at
each assessment (χ2 = 0.4; dl= 1; p = 0.57). First responders
(MADRS< 15) were observed after 10 rTMS session in both
groups (Table 1). More than 50% of patients were responders
at the end of the study period (4weeks).
Effect of treatment (time) was signiﬁcant in both group
[F (4,44) = 15.42; p< 10−7]. No signiﬁcant statistical difference
was observed for MADRS scores between the two groups
[F (1,11) = 0.32; p = 0.58]. We reported no interaction between
Table 1 | Characteristics of patients throughout the study period.
1Hz (n=8) 10Hz (n=6) p
BASELINE CHARACTERISTICS
Age 46.1 (16.3) 50.8 (9.4) 0.54*
Gender (male/female) 2/6 4/2 0.27
†
Inpatient/outpatient 2/6 2/4 0.9*
MADRS 32.0 (8.0) 29.8 (6.9) 0.59*
AFTER 5 rTMS SESSION
MADRS decrease (%) −15.39 (12.02) −19.78 (10.57)
Responders (%) 0 0
AFTER 10 rTMS SESSION
MADRS decrease (%) −22.18 (22.65) −34.95 (14.95)
Responders (%) 25 50
AFTER 15 rTMS SESSION
MADRS decrease (%) −29.72 (34.79) −47.11 (19.29)
Responders (%) 37.5 66.7
AFTER 20 rTMS SESSION
MADRS decrease (%) −51.25 (35.35) −52.96 (21.58)
Responders (%) 50 66.7
rTMS: repetitive transcranial magnetic stimulation/MADRS: Montgomery–
Asberg Depression Rating Scale. Results are given as mean (SD).
*Student t-test; †Fischer Chi-square test.
Responders were deﬁned as patients with a MADRS score <15.
FIGURE 1 | Changes in MADRS scores following rTMS sessions in
combination with venlafaxine (150mg) in both groups: 1Hz applied
over the right dorsolateral prefrontal cortex (DLPFC)/10Hz applied
over the left DLPFC. rTMS: repetitive transcranial magnetic
stimulation/MADRS: Montgomery–Asberg Depression Rating Scale Results
are given as mean and SE.
group (HF or LF) and time [F (4,44) = 0.61; p = 0.66], suggesting
that decreases of MADRS scores were comparable in both groups
(Figure 1).
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DISCUSSION
Our results replicate and extend previous ﬁndings showing that
DLPFC LF-rTMS administered on the right side results in a simi-
lar effect compared to left-sidedDLPFCHF-rTMS (Höppner et al.,
2003; Isenberg et al., 2005; Stern et al., 2007; Fitzgerald et al.,
2009; Pallanti et al., 2010; Rossini et al., 2010). Despite a failure
in response to one previous AD, we reported that some patients
could be considered as responders only 2weeks after the start of
treatment and after 4 weeks, more than a half of group could be
qualiﬁed as responders as deﬁned by a MADRS score<15.
In combination with venlafaxine (150mg/day), 120 pulses/
session of LF-rTMS over the RDLPFC (delivered during 4min)
could be as effective as 2000 pulses/session of HF-rTMS over
the left DLPFC (delivered during 16min). As the most serious
potential side effect of rTMS is seizure, and that LF-rTMS may
be protective against it (Theodore et al., 2002), thus, more than
saving the user and patient time, LF-rTMS should be a treatment
of choice for patients.
We have observed no relapse during the study period (4weeks)
but a follow up period is required before any conclusion on
this point. We reported no adverse events in the combination of
medication.
The lack of an arm with placebo venlafaxine in association
with active rTMS and of an arm with active venlafaxine and
sham rTMS are some limitations of our study. However, it has
been reported that 1Hz rTMS is as effective as venlafaxine in
the treatment of resistant depression (Bares et al., 2009). More-
over, it is important to note that in a large randomized controlled
trial using venlafaxine alone (Rush et al., 2006), with a demo-
graphic comparable depressed group, among the patients who had
a remission (24.8% of the sample), the mean time to remission
was 5.5± 4.7 weeks (median, 4.2). We reported more than 50%
decrease of MADRS score after 4 weeks of treatment while a 30%
decrease of HDRS was reported in a large study investigating the
impact of venlafaxine after previous AD failure (Baldomero et al.,
2005). On the other hand, as it seems to be the case in our results,
Rumi et al. (2005) have reported that in add-on therapy rTMSmay
be able to accelerate the delay efﬁcacy of AD.
In conclusion, although limited by small sample size and lack
of venlafaxine placebo arm, in a sample of patients who have not
responded to one trial of antidepressant medication, in combi-
nation with venlafaxine 150mg/day, right-sided LF-rTMS seems
as effective as left-sided HF-rTMS. In order to investigate the
real impact of LF-rTMS without any antidepressant treatment
compared to rTMS in add-on therapy with venlafaxine and to
venlafaxine alone, we have started a large multicentric study
(clinicaltrials.gov; NCT00714090).
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